Frequency of all Adverse Events 6 years [clinicaltrials_resource:56025cbd1baff9502012e4fde2516941]

Frequency of all Adverse Events 6 years [clinicaltrials_resource:56025cbd1baff9502012e4fde2516941]

750mg Intravenous, monthly and individual dosing schedule
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:56025cbd1baff9502012e4fde2516941
Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome [clinicaltrials:NCT00097370]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Frequency of all Adverse Events 6 years [clinicaltrials_resource:56025cbd1baff9502012e4fde2516941]

750mg Intravenous, monthly and individual dosing schedule
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:56025cbd1baff9502012e4fde2516941
Bio2RDF identifier
56025cbd1baff9502012e4fde2516941
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:56025cbd1baff9502012e4fde2516941
measure [clinicaltrials_vocabulary:measure]
Frequency of all Adverse Events
time frame [clinicaltrials_vocabulary:time-frame]
description
750mg Intravenous, monthly and individual dosing schedule
identifier
clinicaltrials_resource:56025cbd1baff9502012e4fde2516941
title
Frequency of all Adverse Events 6 years
@en
inDataset
type
label
Frequency of all Adverse Event ...... 25cbd1baff9502012e4fde2516941]
@en